Health · Medical Research · 2 hrs ago

Pancreatic cancer vaccine triggers immune response but does not improve survival

Pancreatic cancer vaccine triggers immune response but does not improve survival

A phase 2 trial tested camupepimut in 144 people with KRAS-mutated pancreatic cancer who had surgery and chemotherapy and no detectable cancer afterward.

Pancreatic cancer often returns after treatment, so researchers wanted to see whether the vaccine could help the body find and destroy cancer cells left behind.

The vaccine trains the immune system to recognize mutations in the KRAS gene, which are common in this cancer.

It did not significantly extend disease-free survival: the average was 23.8 months for vaccinated patients and 21.2 months for those who were observed without the vaccine.

Nearly 99 percent of vaccinated patients developed stronger T-cell responses against the mutations, and most still had detectable responses after 46 weeks.

Some patients may benefit more, including those with no detectable cancer DNA in their blood at the start of the study; patients who had not received radiotherapy also appeared to respond better.

Researchers plan to refine the vaccine and use the findings to develop a larger phase 3 trial.

1 source

Related

What people are saying

Ben GeorgeLead study author and Mayo Clinic medical oncologist
The immune response is an important signal that helps us understand what is happening biologically and gives us important information for the next trial,
via Discover
What is encouraging is that we were able to generate a strong immune response against KRAS mutations in nearly every patient we evaluated.
via Discover